Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary
Sponsors
Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years old; 2. Patients diagnosed with novel coronavirus pneumonia (COVID-19); 3. Patients >=21 days since the first symptoms ; 4. The diagnosis of pulmonary fibrosis is based on the chest CT (such as fibrotic changes in multiple lungs with patchy ground glass or with consolidation, lobular septal thickening, grid, stripe shadow, etc.) or other examination results; 5. The subject must meet at least one of the following two criteria: (1) Pulmonary function examination, showing restricted ventilation dysfunction and / or impaired gas exchange, FVC 70%, DLCO <80% predicted value; (2) Shortness of breath after exercise or need oxygen therapy support; 6. Voluntarily participate in this study, agree to comply with the requirements of the clinical research protocol, and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are using invasive mechanical ventilation for respiratory support; 2. Patients with recent hemodynamic instability requiring maintenance of vasoactive drugs and determined by the investigator to be unsuitable to participate in this clinical study; 3. Patients with other severe basic lung diseases, such as active tuberculosis, bronchiectasis, chronic obstructive pulmonary disease, pulmonary hypertension, and damaged lungs, etc., and the researchers judge that they are not suitable to participate in this clinical study; 4. Complicated with severe vascular diseases, such as severe cardiac dysfunction (cardiac function ?, ?), or suffered from acute coronary syndrome, acute cerebrovascular event, deep vein thrombosis or pulmonary embolism within 6 months before enrollment, and Researchers judge it inappropriate to participate in this study; 5. Poorly controlled hypertension, diabetes, severe liver, kidney, coagulation dysfunction, or the effects of other diseases, and it is not appropriate for the study to be judged by the researcher; 6. Those with malignant tumors or pathology suggesting a history of severe atypical hyperplasia; 7. Positive test for human immunodeficiency virus (HIV) antibody, hepatitis C virus antibody, Treponema pallidum antibody, and patients with active infectious diseases that other researchers consider unsuitable to participate in this study; 8. Have a history of severe drug allergies, or are allergic to the main active ingredients or excipients of clinical research products; 9. Those who have previously received cell therapy or organ transplants; 10. Women who are pregnant or nursing or plan to become pregnant during the study, or women or men of childbearing age who are unwilling to take contraception throughout the study; 11. Patients who have been treated with other clinical research products within 28 days before starting treatment, and the researcher determines that the relevant clinical research products will interfere with the evaluation of the safety and effectiveness of this clinical research product; 12. The investigator believes that patients participating in this study are not in the best interest or are not suitable for other conditions such as poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of life quality ;Evaluation of mental health;Blood immune factor test; | — |
Countries
China
Contacts
Public ContactZhang Dingyu
Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
Outcome results
None listed